Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nanobiotix
Memgen, Inc.
Exelixis
Compugen Ltd
Jonsson Comprehensive Cancer Center
Tempest Therapeutics
Calithera Biosciences, Inc
Infinity Pharmaceuticals, Inc.
Sheba Medical Center
Celgene